Clinical trials in gynecologic oncology: Past, present, and future.
Clinical trials in gynecologic oncology: Past, present, and future.
复制标题
妇科肿瘤学临床试验：过去、现在和未来。
DOI：
10.1016/j.ygyno.2017.11.026
复制
发表时间：
2018
影响因子：
4.7
通讯作者：
Kohn,EliseC
中科院分区：
文献类型：
--
作者：
Annunziata,ChristinaM;Kohn,EliseC
妇科肿瘤小组历来在妇女癌症方面进行了突破性的、改变实践的临床试验。目前卵巢癌、子宫内膜癌、宫颈癌和滋养细胞癌初始治疗的护理标准是由在这个合作小组结构中完成的临床试验确定的。例如，GOG-0111试验为卵巢癌联合铂和紫杉烷化疗制定了标准，最近的GOG-0240试验为晚期宫颈癌妇女的化疗中加入贝伐单抗提供了证据。近几十年来，临床试验设计的格局发生了显著变化，明确强调针对特定患者群体和研究药物的适应症简化药物开发。妇科癌症的转化科学可以为我们的患者快速有效地引入新疗法奠定基础。妇科肿瘤学研究人员和临床医生已经准备好进入药物开发的新时代，突破性发现每年都在增加。很明显，我们必须结合更聪明的临床试验设计，以便尽快为正确的患者提供正确的药物，这样我们才能继续改善患有妇科癌症的妇女的预后。
The Gynecologic Oncology Group has historically performed ground-breaking, practice-changing clinical trials in women's cancers. The current standard of care for initial treatment of ovarian, endometrial, cervical, and trophoblastic cancers was determined by clinical trials completed within this cooperative group structure. For example, trial GOG-0111 set the standard for combining platinum and taxane chemotherapy in ovarian cancer, and more recently GOG-0240 provided evidence for adding bevacizumab to chemotherapy for women with advanced cervical cancer. The landscape of clinical trial design has markedly changed in recent decades, with a clear emphasis on streamlining drug development towards specific patient populations and indications for investigational agents. Translational science in gynecologic cancers can set the stage for rapid and efficient introduction of new therapies for our patients. The gynecologic oncology community of researchers and clinicians is well positioned to enter into the new era of drug development, with breakthrough discoveries increasing each year. It is clear that we must incorporate smarter clinical trial design to get the right drugs to the right patients expeditiously, so we can continue to improve outcome for women with gynecologic cancers.